Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | XDH | P47989 | 1/20 | 0.51 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMO | O15229 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL60691 | 1.00 | GSK3B (0.62) | GSK3BCA12CA1CA2CA6 | |
| SCHEMBL27804665 | 0.98 | GSK3B (0.61) | GSK3BCA12CA1CA2CA6 | |
| Hydrochloric Acid SCHEMBL2031438 | 0.98 | GSK3B (0.61) | GSK3BCA12CA1CA2CA6 | |
| SCHEMBL11706688 | 0.98 | GSK3B (0.61) | GSK3BCA12CA1CA2CA6 | |
| SCHEMBL27820119 | 0.98 | GSK3B (0.61) | GSK3BCA12CA1CA2CA6 | |
| SCHEMBL6832704 | 0.93 | GSK3B (0.56) | GSK3BXDHSLC22A12MRGPRX4 | |
| SCHEMBL5529069 | 0.89 | XDH (0.62) | GSK3BXDHSLC22A12KMO | |
| SCHEMBL4030533 | 0.87 | GSK3B (0.54) | GSK3BMRGPRX4HTTHSD17B10 | |
| SCHEMBL29724115 | 0.86 | GSK3B (0.57) | GSK3BXDHSLC22A12MRGPRX4GRM5 | |
| SCHEMBL6895867 | 0.85 | GSK3B (0.60) | GSK3BMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025243250-A1 | A PROCESS FOR THE PREPARATION OF 3-[5-(2-FLUOROPHENYL)-1,2,4-OXADIAZOL-3-YL]BENZOIC ACID | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2025-11-27 | — | — | WO | claimed |
| WO-2025126110-A1 | ENT1 INHIBITORS IN COMBINATION WITH BISPECIFIC ANTIBODIES | iTeos Belgium SA (BE) | 2025-06-19 | — | — | WO | claimed |
| CN-120020114-A | Preparation method of N-alkenyl amide compound | 中国石油化工股份有限公司 | 2025-05-20 | — | — | CN | claimed |
| EP-4148039-B1 | METHOD FOR PREPARING PHTHALONITRILE-BASED COMPOUND | KOREA KUMHO PETROCHEMICAL CO LTD (KR) | 2026-03-11 | — | — | EP | disclosed |
| WO-2025243250-A1 | A PROCESS FOR THE PREPARATION OF 3-[5-(2-FLUOROPHENYL)-1,2,4-OXADIAZOL-3-YL]BENZOIC ACID | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2025-11-27 | — | — | WO | disclosed |
| WO-2025202864-A1 | ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER | iTeos Belgium SA (BE) | 2025-10-02 | — | — | WO | disclosed |
| US-12415778-B2 | Method for preparing phthalonitrile-based compound | KOREA KUMHO PETROCHEMICAL CO., LTD. (KR) | 2025-09-16 | — | — | US | disclosed |
| US-12410210-B2 | Neuroactive steroids and their methods of use | SAGE THERAPEUTICS, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| WO-2025126110-A1 | ENT1 INHIBITORS IN COMBINATION WITH BISPECIFIC ANTIBODIES | iTeos Belgium SA (BE) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025104613-A1 | ENT1 INHIBITORS IN COMBINATION WITH CHECKPOINT INHIBITORS | iTeos Belgium SA (BE) | 2025-05-22 | — | — | WO | disclosed |
| CN-120020114-A | Preparation method of N-alkenyl amide compound | 中国石油化工股份有限公司 | 2025-05-20 | — | — | CN | disclosed |
| WO-2023038411-A1 | METHOD FOR PREPARING PHTHALONITRILE-BASED COMPOUND | 금호석유화학 주식회사 | 2023-03-16 | — | — | WO | disclosed |
| EP-4148039-A1 | METHOD FOR PREPARING PHTHALONITRILE-BASED COMPOUND | Korea Kumho Petrochemical Co., Ltd. (KR) | 2023-03-15 | — | — | EP | disclosed |
| CN-115784932-A | Method for preparing phthalonitrile compounds | 锦湖石油化学株式会社 | 2023-03-14 | — | — | CN | disclosed |
| EP-4143195-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | Janssen Pharmaceutica NV (BE) | 2023-03-08 | — | — | EP | disclosed |
| WO-2023279938-A1 | 2,6,8-POLYSUBSTITUTED IMIDAZO[1,2-A]PYRAZINE, AND SYNTHESIS METHOD THEREFOR AND USE THEREOF | 无锡市第二人民医院 | 2023-01-12 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2022140520-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| EP-3997081-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | Escape Bio, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| WO-2022035805-A1 | SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410210-B2 | Neuroactive steroids and their methods of use | NR3C2, MC2R, NR3C1 | GSK3B 524/4885CA12 2114/4885CA1 1422/4885 |
| US-12415778-B2 | Method for preparing phthalonitrile-based compound | PNN, INF2, DCX | GSK3B 4837/4885CA12 2449/4885CA1 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.